Cerevel Therapeutics stock (US15671R1077): focus remains on AbbVie takeover as trading continues on Nasdaq

Cerevel Therapeutics shares continue to trade on Nasdaq as investors await the closing of the agreed AbbVie acquisition, with the biotech remaining in focus among US neuroscience names.

Cerevel Therapeutics remains in the spotlight for US investors as trading in the biotechnology stock continues on Nasdaq while the market waits for the closing of its agreed takeover by AbbVie, keeping attention on deal timing and regulatory milestones in the United States.

The company, which is headquartered in Cambridge, Massachusetts, and listed on Nasdaq under the ticker CERE, agreed in December 2023 to be acquired by AbbVie in a cash transaction valuing the equity at about USD 8.7 billion, according to the companies' joint announcement filed with the US Securities and Exchange Commission at the time.

Under the terms of that agreement, AbbVie offered USD 45.00 in cash per Cerevel share, with the transaction framed as a way to expand AbbVie's neuroscience pipeline through Cerevel's portfolio of experimental therapies targeting psychiatric and neurological disorders, as set out in the deal press release filed in December 2023.

Regulatory and shareholder approvals have been key checkpoints since then, and while the stock continues to trade on Nasdaq, market participants are watching for further updates from US regulators and the companies' investor relations channels on the expected closing date and any remaining conditions associated with the merger.

In the United States, the stock remains part of the listed biotech universe on Nasdaq, which is a core venue for high-growth healthcare and life sciences names, and Cerevel's presence there anchors the story firmly in its home market for both equity and M&A activity.

Recent sector commentary from US media has highlighted how large pharmaceutical groups such as AbbVie have turned to targeted acquisitions in neuroscience and psychiatry to replenish pipelines as legacy products mature, placing deals like the one for Cerevel in the broader context of strategic portfolio reshaping across the industry.

On European platforms used by German investors, Cerevel shares are also available via trading venues such as Tradegate and Frankfurt, typically quoted in euros on an over-the-counter basis that references the primary Nasdaq price in US dollars.

As a result, retail investors in Germany can follow the same transaction-driven narrative that US investors see on Nasdaq, even though liquidity and spreads are generally deepest and tightest on the home-market listing in the United States.

The offer price of USD 45.00 per share from AbbVie has provided a key reference point for trading, with the market price of Cerevel generally anchored by the implied deal value while still reflecting residual uncertainty over timing, regulatory review, and the low but non-zero risk that complex biotech transactions can occasionally face delays or changes to their terms.

As of 05/29/2026, the stock remained an actively traded US biotech name rather than a completed delisting, meaning that the acquisition is still seen by the market as pending rather than fully closed, based on the continued presence of a standalone Nasdaq quotation and absence of a completed delisting notice from the exchange or the companies.

PENDING

As of: 29.05.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: CERE
• Sector/industry: Biotechnology - neuroscience and psychiatry
• Headquarters/country: Cambridge, United States
• Core markets: United States and other major pharmaceutical markets
• Key revenue drivers: Late-stage neuroscience pipeline and collaboration payments
• Home exchange/listing venue: Nasdaq (CERE)
• Trading currency: USD

Cerevel Therapeutics: core business model

Cerevel Therapeutics focuses on developing central nervous system therapies that aim to address neurological and psychiatric conditions, with value creation closely tied to the clinical and regulatory progress of its drug candidates.

Valuation metrics and multiples for Cerevel Therapeutics

Because Cerevel remains in the process of being acquired by AbbVie at a fixed cash price of USD 45.00 per share according to the original deal terms from December 2023, traditional valuation metrics such as forward price-to-earnings or enterprise value to EBITDA play a secondary role to the agreed transaction value when investors assess the stock.

For many merger-arbitrage participants and event-driven funds, the spread between the current trading price of Cerevel on Nasdaq and the USD 45.00 offer price effectively acts as the primary valuation signal, embedding the market's assessment of regulatory risk, time to closing, and the probability of completion, rather than a standalone view on long-term earnings-based valuation multiples.

Conclusion

With Cerevel Therapeutics still trading on Nasdaq and the AbbVie cash offer of USD 45.00 per share acting as the central valuation reference, the stock remains primarily shaped by merger-related dynamics rather than standalone earnings expectations.

The valuation lens for many market participants is therefore dominated by the spread to the offer price, perceived regulatory and execution risks in the United States, and the strategic rationale of AbbVie's push into neuroscience, rather than traditional metrics such as price-to-earnings or enterprise value multiples.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.